Healthy Skepticism Library item: 13270
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Druss BG, Marcus SC, Olfson M, Pincus HA.
Listening to generic Prozac: winners, losers, and sideliners.
Health Aff (Millwood) 2004 Sep-Oct; 23:(5):210-6
http://content.healthaffairs.org/cgi/content/full/23/5/210
Abstract:
This study tracks the diffusion of generic fluoxetine after its release in August 2001 within the largest U.S. pharmacy benefit manager (PBM). Within two weeks of the generic’s release, prescriptions exceeded those of brand-name Prozac. The main winners proved to be Barr Laboratories, the first entrant to the generic market; large purchasers, who reaped substantial cost savings after Barr’s period of exclusivity expired; and the PBM. The major loser was Eli Lilly, the manufacturer of Prozac. Consumers and makers of other antidepressants largely remained on the sidelines, with surprisingly little short-term impact evident from Prozac’s patent expiration.
Keywords:
Publication Types:
Comparative Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Adolescent
Adult
Aged
Antidepressive Agents, Second-Generation*/economics
Drug Industry/economics
Drugs, Generic*/economics
Female
Fluoxetine*/economics
Humans
Male
Middle Aged
United States
Substances:
Antidepressive Agents, Second-Generation
Drugs, Generic
Fluoxetine
Notes:
Free full text
